Chris’ note: First off, we want to wish all our readers a happy Thanksgiving. We hope you’re enjoying time with your families. In the meantime, we have a special essay for you from one of our most trusted experts…
Few investors are better at zeroing in on game-changing tech trends (before they hit the mainstream) than my friend and colleague Jeff Brown.
Jeff learned the ins and outs of the tech world through his decades of experience in Silicon Valley. He’s done it all, from being involved in early-stage startups to serving as a high-ranking executive at Qualcomm and NXP Semiconductors.
And he has a knack for spotting companies set to benefit from groundbreaking trends, which led him to recommend the No. 1 stock in the S&P 500 in 2016 and 2018.
That’s why today, we’re handing the reins to Jeff to tell you about the latest innovation he sees in the biotech sector. It has the potential to transform medicine as we know it… and it could affect the lives of millions of people.
I’ll let Jeff explain the rest below…
By Jeff Brown, editor, Exponential Tech Investor
Grace Wilsey couldn’t cry…
As a baby, she would lie limp in her parents’ arms, staring blankly into the distance. Her seizures wouldn’t stop. Medical tests showed signs of liver damage. This was all before her second birthday.
Grace’s parents were beside themselves, as any parent would be. They traveled the country visiting specialists. They ran numerous tests, but no one could diagnose Grace’s condition.
“We’ve probably seen over 100 doctors,” Grace’s father said in 2014 when Grace’s symptoms were discovered.
None of them could provide an explanation.
Then, when their daughter turned 2 years old, the Wilseys tried something else. And it’s the reason I’m telling you her story today… because it’s a sign of a revolution that will transform the medical industry…
The Wilseys had Grace’s entire genome sequenced.
A genome is an organism’s complete set of DNA, including all its genes. Genome sequencing is the process of determining the complete DNA sequence. Think of it like creating a “genetic roadmap,” a complete blueprint of an organism’s genetic material.
What the test showed was astounding…
Grace Wilsey had a condition known as NGLY1 deficiency. In short, the little girl’s NGLY1 genes were mutated. They were like typos in her genetic makeup.
One of the gene mutations prevented her from producing tears. At the time, the disorder was so rare that only six people in the entire world had been diagnosed with it.
This story is just one of millions. It is estimated that over 300 million people suffer from a rare genetic disease. Many of them often live their lives undiagnosed.
But there is hope on the horizon.
The cost of sequencing a human genome has plummeted. The speed of the sequencing technology has grown exponentially. And thanks to breakthroughs in genetic editing technology, we’re on the verge of a complete transformation in medical care.
Soon, we’ll be able to identify genetic diseases like cystic fibrosis or sickle cell anemia years before symptoms present themselves. Then, we’ll be able to fix the genetic mutation that caused the underlying condition.
Millions of lives will be saved. Hundreds of billions of dollars typically spent on chronic medical care will be eliminated. It will be the biggest revolution in health care since the invention of antibiotics.
A Medical Revolution
These days, we typically wait until we feel sick before we seek medical treatment. Then, we visit a hospital where our symptoms are treated.
Very often, each patient is treated with a “one size fits all” therapy. This approach to medicine is reactionary. In the very near future, medicine will be proactive and personalized.
The technique the Wilseys used to diagnose their daughter – genetic sequencing – will be common practice. We’ll be able to “blueprint” our DNA and identify early indicators of disease.
And the cost of genetic sequencing is plummeting in price. Take a look at the chart below. It maps the average cost to sequence – or blueprint – a human genome.
As you can see, in 2001, it cost a staggering $100 million to sequence all of a human’s genetic material.
But look at where the cost is today. According to data published by the National Human Genome Research Institute, a division of the National Institutes of Health, the cost dropped to $606 as of May this year. No kidding.
The decline in cost for genetic sequencing has been accelerating far faster than Moore’s Law. As a reminder, Moore’s Law is the “gold standard” for exponential growth in the field of high technology. At this rate, the cost to sequence a human genome will quickly hit $100.
And that changes everything.
Insurers Get On Board
When costs decline, insurers get on board with genetic sequencing…
As of November 1, 2017, UnitedHealthcare began covering “whole exome sequencing for patients where clinical presentation is non-specific and does not fit a well-defined syndrome.”
In other words, if a physician knows something is wrong, but can’t figure out what it is, UnitedHealthcare will pay to have the patient’s whole exome sequenced.
And on December 1, Cigna will be in-network with direct-to-customer genetic testing screenings. This will give 16 million lives easy access to genetic sequencing.
Think of how much time and pain can be saved when a genetic sequence can tell us almost immediately what is wrong… rather than spending years and potentially millions of dollars pursuing ineffective or sometimes lethal therapies.
But identifying a genetic disorder is only the first step. Once we identify a mutated gene, a therapy must be administered to “fix” the mutation.
That’s where things get very interesting.
The God Key
The technology that will fix the “typos” in our genetic material is called CRISPR-Cas9.
It stands for Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9. I know. It’s a mouthful. I typically refer to this technology as just CRISPR (pronounced “crisper”).
CRISPR technology can “edit” our DNA as if it were software code. It’s a way to “program” the genome and remove the “typos” – or, in genetic terms, the “mutations” – from DNA.
I’ve referred to CRISPR technology as “The God Key” because of the powerful potential to improve the human condition.
And we’re getting early indications that CRISPR technology works.
In February, one of the leading CRISPR companies dosed the first patient for a therapy to treat a genetic blood disorder – beta thalassemia.
As of November, we heard that the patient has not required a blood transfusion for more than nine months. Patients who have beta thalassemia usually require blood transfusions as often as every two to four weeks.
And there’s more.
Victoria Gray is the first person in the United States to be treated with CRISPR for sickle cell disease. Gray was treated months ago, in a clinical trial administered by Vertex Pharmaceuticals.
It’s still early days, but it looks like the CRISPR treatment is working for Victoria. Early results are positive. In fact, she called her edited bone marrow cells “supercells.”
There are an estimated 6,000 known genetic diseases. CRISPR genetic editing has the potential to cure every one of them permanently.
With genetic sequencing and CRISPR genetic editing, we will live well into our hundreds. And we’ll enjoy a great quality of life along the way.
This is the future of medicine.
And it’s approaching faster than most realize.
Editor, Exponential Tech Investor
P.S. Investing in the companies behind this technology is a once-in-a-generation opportunity. I estimate the total market opportunity for therapies derived from CRISPR/Cas9 genetic editing to exceed $1 trillion. Essentially, the sky is the limit.
And there is one small-cap CRISPR company that investors need to own today. In the coming days, this company will release the results of its latest trial. I have good reason to believe that trial will be a success. And after the announcement, I predict shares in this small-cap stock will soar as high as 1,000%.
But time is running out. The trial results are fast approaching. If you’d like to get the details before it’s too late, click right here.